Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S

Abstract SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the t...

Full description

Bibliographic Details
Main Authors: Dominique J. Barbeau, Judith M. Martin, Emily Carney, Emily Dougherty, Joshua D. Doyle, Terence S. Dermody, Alejandro Hoberman, John V. Williams, Marian G. Michaels, John F. Alcorn, W. Paul Duprex, Anita K. McElroy
Format: Article
Language:English
Published: Nature Portfolio 2022-07-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00504-x

Internet

https://doi.org/10.1038/s41541-022-00504-x

Similar Items